Lucid Diagnostics Inc. (NASDAQ:LUCD) Q1 2024 Earnings Conference Call May 13, 2024 8:30 AM ET

Company Participants

Matt Riley - Director of IR
Lishan Aklog - Chairman and CEO
Dennis McGrath - CFO

Conference Call Participants

Mike Matson - Needham
Anthony Vendetti - Maxim Group
Vidyun Bais - BTIG
Kyle Mikson - Canaccord
Edward Woo - Ascendiant Capital

Operator

Good morning, and welcome to the Lucid Diagnostics First Quarter 2024 Business Update Conference Call. At this time all lines are in listen only mode. Following the presentation we will conduct a question-and-answer session. [Operator Instructions] Please note this event is being recorded.

I would now like to turn the conference over to Matt Riley, Lucid Diagnostics' Director of Investor Relations. Please go ahead.

Matt Riley

Thank you, operator and good morning, everyone. Thank you for participating in today's business update call. Joining me today on the call are Dr. Lishan Aklog, Chairman and Chief Executive Officer of Lucid Diagnostics along with Dennis McGrath, Chief Financial Officer of Lucid Diagnostics.

The press release announcing our business update and financial results is available on our Lucid website. Please take a moment to read the disclaimer about forward-looking statements in the press release. The business update, press release and the conference call include forward-looking statements, and these forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from statements made. Factors that could cause actual results to differ are described in the disclaimer and in our filings with the Securities and Exchange Commission.

For a list and description of these and other important risk factors and uncertainties that may affect future operations, see Part I, Item 1A entitled Risk Factors in Lucid's most recent annual report on Form 10-Q filed with the SEC and any subsequent updates filed in quarterly reports on Form 10-Q and subsequent filings on Form 8-K. Except as required by law, Lucid disclaims any intentions or obligations to publicly update or revise any forward-looking statements to reflect changes and expectations or in events, conditions or circumstances on which the expectations may be based or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

I'd like to turn the call over to Dr. Lishan Aklog, our Chairman and CEO of Lucid Diagnostics. Lishan, take it away.

Lishan Aklog

Thank you, Matt, and good afternoon, everyone. Thank you for joining our quarterly update call today. I also like to thank our long-term shareholders for your ongoing support and commitment. Our team here at Lucid is singularly focused on driving our enterprise towards what we believe is a massive commercial potential and to enhance our long-term shareholder value. Very pleased with the excellent progress the team has made over on multiple fronts during the first quarter and the start of this year and really look forward to very exciting very near-term milestones for our business.